Postmarketing Trial
FDA Responds to Safety Signal Reported in Required Postmarketing Trial for Xeljanz
U.S. Food & Drug Administration
PR-M02-19-NI-068Feb 28, 2019
Rheumatology
Mallinckrodt Presents Data on H.P. Acthar® Gel (Repository Corticotropin Injection) in Rheumatoid Arthritis (RA) at the 2018 ACR/ARHP Annual Meeting
Mallinckrodt Pharmaceuticals
PR-M10-18-NI-092Oct 26, 2018
Rheumatology
New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting
Eli Lilly and Company
PR-M10-18-NI-062Oct 18, 2018